Overactive Bladder Treatment Market Trends

Global Overactive Bladder Treatment Market Overview

Overactive Bladder Treatment Market Size was valued at USD 2.74 billion in 2023. The Overactive Bladder Treatment Market industry is projected to grow from USD 2.85 Billion in 2024 to USD 3.6 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 2.95% during the forecast period (2024 - 2032). According to the data published by the National Institutes of Health (NIH) in 2020, COVID-19 infection increased urine cytokine levels and the frequency of urination. As a result, COVID-19 is the primary market driver for the rise in demand for Overactive bladder treatment. 

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Overactive Bladder Treatment Market Trends

• Increasing incidence of neurological diseases boost market growth

Several drugs, including antiepileptics, antipsychotics, analgesics, and anticholinergics, treat neurological illnesses. The aging population is driving market expansion and increased spending on developing new drugs and devices. Additionally, government regulatory agencies and private organizations are expected to launch awareness campaigns to raise public awareness about early disorder diagnosis. Effective drugs will soon enter the market due to a robust drug pipeline, which is expected to fuel market growth.

However, the rising frequency of neurological illnesses like dementia and the growing number of government programs to raise awareness positively impacted the market trend during the projection period. Additionally, it is anticipated that the market will rise faster during the projected period due to increasing investments in creating innovative technologies and expanding emerging markets.

Market participants' strategic actions are also anticipated to fuel the market segment's expansion. For instance, the eCoin leadless tibialneurostimulator from Valencia Technologies Corporation was given premarket approval (PMA) by the US Food and Drug Administration (FDA) in March 2022 to treat urine urge incontinence (UUI), which affects more than 60% of patients with overactive bladder (OAB). These approvals are anticipated to aid in the market segment's expansion.

Therefore, the medical condition has recently enhanced the Overactive Bladder Treatment Market CAGRacross the globe.

However, there have been significant advances in treatment innovations to cater to the demand. Understanding the characteristics of the pharmaceuticals and their application in treating chronic diseases, along with quick medical research and development, are other factors driving the growth of the Overactive Bladder Treatment Market revenue.

Overactive Bladder Treatment Market Segment Insights

Overactive Bladder Treatment By Pharmaco therapy Insights

The Overactive Bladder Treatment Marketsegmentation is based on pharmacology into Anticholinergic, Botox. The Anticholinergic segment is expected to hold the most prominent  Overactive Bladder Treatment Market revenue in 2022 and the highest CAGR over the forecast period. Strategic moves made by market players are also expected to support the market segment's growth. FDA approved premarket clearance (PMA) for Valencia Technologies Corporation's eCoin leadless tibialneurostimulator in March 2022 to treat urine urge incontinence (UUI), which affects more than 60% of individuals with overactive bladder (OAB). The expansion of the market sector is predicted to benefit from these approvals. Strategic moves made by market players are also expected to support the market segment's growth. US Food and Drug Administration (FDA) granted premarket clearance (PMA) for Valencia Technologies Corporation's eCoin leadless tibialneurostimulator in March 2022 to treat urine urge incontinence (UUI), which affects more than 60% of individuals with overactive bladder (OAB). These approvals are anticipated to aid in the market segment's expansion.

The prevalence of UI is expected to aid in the market's growth. In the 2022 Census, there were roughly 7,021,430 people 65 and older; 3,224,680 were men, and 3,796,750 were women. National Association for Continence estimates that an estimated 25 million adult Americans experience acute or chronic urine incontinence. UI is more likely to affect older women than younger ones.

February 2022 Alembic Pharmaceutical got approval from the US health regulator for its generic formulation of fesoterodinefumarate extended-release tablets, used to treat overactive bladder in adults with symptoms of urinary incontinence and frequency.

September 2022 Axonics announces the first patient implants using Canada's new recharge-free sacral neuromodulation technology. Following U.S. FDA approval, the Axonics F15 receives regulatory approval from Health Canada.

Figure 1  Overactive Bladder Treatment Market, By Pharmacotherapy , 2022& 2030 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Overactive Bladder Treatment By Non-Pharmacological Treatment Insights

The Overactive Bladder Treatment Market data is based on non-pharmacological treatment is segmented into behavioral therapy. Overactive bladder (OAB) can be effectively treated with behavioural counselling, which is frequently suggested as the first course of action. Exercises for the pelvic floor muscles, dietary changes, and bladder training are just a few of the methods used in behavioural treatment for OAB. In order to increase bladder capacity and decrease frequency of urination, bladder training involves progressively lengthening the time between voids.

Overactive Bladder Treatment By Disease Insights

The Overactive Bladder market data based on disease, is divided into Idiopathic Overactive Bladder. Overactive bladder (OAB) with an unclear aetiology is referred to as idiopathic OAB. A sudden and urgent need to urinate is a defining feature of OAB, which is frequently followed by frequency and nocturia (waking up at night to urinate). There is no underlying neurological, metabolic, or other medical disease that can account for the symptoms in idiopathic OAB.

April 2021 Medtronic plc announced authorization to go from the US Food and Drug Administration (FDA) to go forward with an investigational device exemption (IDE) trial to test its internally developed implantale tibial neuromodulation (TNM) device in the Overactive bladder treatment industry, a therapy that they developed to provide relief from symptoms of bladder incontinence.

May 2022 Urovant Sciences, a wholly owned subsidiary of Sumitovant Biopharma Ltd., presented data from the Phase 3 EMPOWUR Extension Study of GEMTESA(vibegron) 75 mg overactive bladder therapy. It will further confirm this drug’s potential utility and durability in this patient population and examine the long-term effects of the product.

Overactive Bladder Treatment Regional Insights

The overactive bladder treatment market insights comprise four regions the Americas, Europe, Asia-Pacific, the Middle East, and Africa. North America Overactive bladder Treatment Market is expected to lead the market in the Americas owing to the increasing geriatric population, Rising cases of OAB, and the availability of different healthcare market report coverage systems like Medicare.

Figure 3 OVERACTIVE BLADDER TREATMENT MARKET SHARE BY REGION 2022 (%)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe overactive bladder treatment market will be second largest market. According to estimates, the rising market rates in this region are attributed to the increasing incidences of OAB and the availability of reimbursements for a specific treatment option. For instance, Botox therapy is reimbursed by the UK’s National Institutes for Health and Care Excellence (NICE). Further, the UK overactive bladder treatment Market held the largest market share, and the Germany overactive bladder treatment Market was the fastest growing market in the region

The Asia-Pacific Overactive Bladder Treatment Market is anticipated to be the fastest growing region due to the rising prevalence of the Overactive bladder treatment market, growing geriatric population, rising healthcare expenditure, and increasing awareness about overactive bladder condition. Further, the China overactive bladder treatment Market held the largest market share, and the India overactive bladder treatment Market was the fastest growing market in the region

Overactive Bladder Treatment Key Market Players& Competitive Insights

Major market players are investing significantly in R&D to diversify their product lines, which will further help the Overactive Bladder Treatment Market grow. Market participants are also engaging in a wide range of strategic activities to expand their  footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Overactive Bladder Treatment industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market atmosphere.

One of the primary business strategies manufacturers adopt in the  Overactive Bladder Treatment industry to benefit clients and expand the market sector is manufacturing locally to minimize operating costs. The Overactive Bladder Treatment industry has provided medicine with some of the most significant advantages in recent years. The Overactive Bladder Treatment Market's major players, including Astellas Pharma Inc. (Japan), Teva Pharmaceutical Co. (Israel), Medtronic PIc (Ireland), and others, are an attempt to expand the market demand by investing in R&D initiatives.

Alembic Pharmaceuticals Ltd. is an Indian multinational pharmaceutical company headquartered in Vadodara. It is involved in manufacture of pharmaceutical products, pharmaceutical substances and intermediates. It is also termed to be a market leader in macrolides segment of anti-infective drugs in India Alembic Pharmaceutical got approval from the US health regulator for its generic formulation of fesoterodinefumarate extended-release tablets, used to treat overactive bladder in adults with symptoms of urinary incontinence and frequency.

Medtronic plc is an American medical device company. The company's operational and executive headquarters are in Minneapolis, Minnesota, and its legal headquarters are in Ireland due to its acquisition of Irish-based Covidien.Medtronic plc announced authorization to go from the US Food and Drug Administration (FDA) to go forward with an investigational device exemption (IDE) trial to test its internally developed implantale tibial neuromodulation (TNM) device in the Overactive bladder treatment industry, a therapy that they developed to provide relief from symptoms of bladder incontinence.

Key Companies in the Overactive Bladder Treatment Market includes

• Astellas Pharma Inc.


• Pfizer Inc.


• Teva Pharmaceutical


• Allergan Plc.


• Mylan N.V.


• Endo International Plc


• Hisamitsu Pharmaceutical Co. Inc.


• Sanofi S. A.


• Aurobindo Pharma Limited


• Johnson & Johnson"

Overactive Bladder Treatment industryDevelopments

In July 2022, Dr. Reddy’s Laboratories released fesoterodinefumarate extended-release tablets, a generic therapeutic version of Pfizer’s Toviaz (fesoterodinefumarate) ER tablets in the United States for the therapy of overactive bladder.

In May 2022, Urovant Sciences, a wholly owned subsidiary of SumitovantBiopharma Ltd., presented data from the Phase 3 EMPOWUR Extension Study of GEMTESA(vibegron) 75 mg overactive bladder therapy. It will further study this drug’s potential utility and durability in this patient population and examine the long-term impacts of the medication.

Overactive Bladder Treatment Market Segmentation

Overactive Bladder Treatment by Pharmacotherapy Outlook

• Anticholinergics


• Botox

 Overactive Bladder Treatment, by Non-Pharmacological Outlook

• Behavioral Therapy

 Overactive Bladder Treatment Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America